Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 1/2016

01.03.2016 | Original Article

Study of Methaemoglobin in Malaria Patients

verfasst von: G. C. Behera, S. K. Behera, R. K. Jena, V. S. Bharati

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

To estimate the concentration of methemoglobin (MetHb) in malaria patients and correlate with severity of malaria infection. This prospective study included 30 untreated cases of malaria confirmed by Quantitative Buffy Coat (QBC) test and 30 age sex matched non-malarial cases taken as controls. All the patients underwent thorough clinical examination and routine biochemical investigation. Methemoglobin levels were estimated by spectrophotometric (co-oxymeter) method on day 1 and day 10 of diagnosis of all study group patients and correlated with clinical profile and severity. Out of 30 malaria patients 22 were males and eight were females. The clinical presentations in complicated malaria group (n = 21) were fever 21 (100 %), anemia 17 (80.95 %), renal failure 12 (52.38 %) and coma/convulsion 5 (23.8 %). The mean age of the study group was 41.66 years. Mean MetHb in complicated malaria on day 1 was 2.55 ± 1.75 % and day 10 was 10.69 ± 8.19 % (statistically significant). The overall mortality was 13 (43.33 %) among study group while 5 (16.66 %) was found among control group. Mean MetHb who died (n = 13) on day 1 was 3.144 ± 1.829 % and (n = 8) on day 10 it was 19.982 ± 8.406 %. Increase in level of methaemoglobin is detrimental to the body and is associated with increase in mortality. Routine MetHb estimation may be used as a prognostic indicator in the management of malaria patients. It is suggested that addition of drugs which reduce MetHb may be tried along with antimalarial drugs to decrease morbidity and mortality in malaria.
Literatur
1.
Zurück zum Zitat Prchal JT et al (2005) Red cell enzymes. Hematology Am Soc Hematol Educ Program 1:19–23CrossRef Prchal JT et al (2005) Red cell enzymes. Hematology Am Soc Hematol Educ Program 1:19–23CrossRef
2.
Zurück zum Zitat Wright RO, Lewander WJ, Woolf AD et al (1999) Methemoglobinemia: etiology, pharmacology and clinical management. Ann Emerg Med 34(5):646–656CrossRefPubMed Wright RO, Lewander WJ, Woolf AD et al (1999) Methemoglobinemia: etiology, pharmacology and clinical management. Ann Emerg Med 34(5):646–656CrossRefPubMed
6.
Zurück zum Zitat Erel O, Kocyigit A, Aktepe N, Bulut V (1997) Oxidative stress and antioxidant status of plasma and erythrocytes in patients of vivax malaria. Clin Biochem 8(30):631–639CrossRef Erel O, Kocyigit A, Aktepe N, Bulut V (1997) Oxidative stress and antioxidant status of plasma and erythrocytes in patients of vivax malaria. Clin Biochem 8(30):631–639CrossRef
7.
Zurück zum Zitat Carmona-Fonseca J, Alvarez G, Maestre A (2009) Methemoglobinemia and adverse events in plasmodium vivax malaria patients associated with high doses of primaquine treatment. Am J Trop Med Hyg 80(2):188–932PubMed Carmona-Fonseca J, Alvarez G, Maestre A (2009) Methemoglobinemia and adverse events in plasmodium vivax malaria patients associated with high doses of primaquine treatment. Am J Trop Med Hyg 80(2):188–932PubMed
8.
Zurück zum Zitat Kochar DK, Tanwar GS, Khatri PC, Kochar SK, Sengar GS, Gupta A et al (2010) Clinical features of children hospitalized with malaria—a study from Bikaner, northwest India. Am J Trop Med Hyg 83(5):981–989 Kochar DK, Tanwar GS, Khatri PC, Kochar SK, Sengar GS, Gupta A et al (2010) Clinical features of children hospitalized with malaria—a study from Bikaner, northwest India. Am J Trop Med Hyg 83(5):981–989
9.
Zurück zum Zitat Akompong T, Van Wye J, Ghori N, Halder K (1999) Artemisinin and its derivatives are transported by a vacuolar-network of Plasmodium falciparum and their anti-malarial activities are additive with toxic sphingolipid analogues that block the network. Mol Biochem Parasitol 101:71–79 Akompong T, Van Wye J, Ghori N, Halder K (1999) Artemisinin and its derivatives are transported by a vacuolar-network of Plasmodium falciparum and their anti-malarial activities are additive with toxic sphingolipid analogues that block the network. Mol Biochem Parasitol 101:71–79
10.
Zurück zum Zitat Uko EK, Udoke AE, Etukudoh MH (2007) Methaemoglobin profile in malaria infected children in Calabar. Niger J Med 12(2):94–97 Uko EK, Udoke AE, Etukudoh MH (2007) Methaemoglobin profile in malaria infected children in Calabar. Niger J Med 12(2):94–97
11.
Zurück zum Zitat Anstey NM et al (1996) Elevated level of methemoglobin in Tanzanian childrens with severe and uncomplicated malaria. Trans R Soc Trop Med Hyg 90:147–151 Anstey NM et al (1996) Elevated level of methemoglobin in Tanzanian childrens with severe and uncomplicated malaria. Trans R Soc Trop Med Hyg 90:147–151
12.
Zurück zum Zitat Topal H, Topal Y (2013) Toxic methaemoglobinemia treated with ascorbic acid: case report. Iran Red Crescent Med J 15(12):e12718 Topal H, Topal Y (2013) Toxic methaemoglobinemia treated with ascorbic acid: case report. Iran Red Crescent Med J 15(12):e12718
Metadaten
Titel
Study of Methaemoglobin in Malaria Patients
verfasst von
G. C. Behera
S. K. Behera
R. K. Jena
V. S. Bharati
Publikationsdatum
01.03.2016
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 1/2016
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-015-0522-5

Weitere Artikel der Ausgabe 1/2016

Indian Journal of Hematology and Blood Transfusion 1/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.